LOTIS-5: An ongoing, phase 3, randomized study of loncastuximab tesirine with rituximab (Lonca-R) versus immunochemotherapy in patients with R/R DLBCL.

被引：0

作者：

Kwiatek, Michal

Carlo-Stella, Carmelo

Urban, Andrzej

Niewiarowski, Andrew

Wang, Luqiang

Hamadani, Mehdi

机构：

[1] Ctr Med Pratia Poznan, Skorzewo, Poland

[2] Humanitas Univ, Dept Biomed Sci, Milan, Italy

[3] Humanitas Univ, Dept Hematol & Oncol, Milan, Italy

[4] IRCCS Humanitas Res Hosp, Milan, Italy

[5] ADC Therapeut SA, Epalinges, Switzerland

[6] ADC Therapeut Ltd, London, England

[7] ADC Therapeut Amer Inc, Murray Hill, NJ USA

[8] Med Coll Wisconsin, Div Hematol & Oncol, Milwaukee, WI USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS7097

引用

页数：1

共 50 条

[41] Updated results from a phase Ib/II study in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) treated with polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G)
Glass, B.
Sehn, L. H.
Herrera, A. F.
Matasar, M.
Kamdar, M.
Assouline, S.
Hertzberg, M.
Kim, T. M.
Kim, W. S.
McMillan, A.
Ozcan, M.
Hirata, J.
Penuel, E.
Cheng, J.
Ku, G.
Flowers, C. R.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 3 - 3
[42] A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Goy, Andre
Ramchandren, Radhakrishnan
Ghosh, Nilanjan
Munoz, Javier
Morgan, David S.
Dang, Nam H.
Knapp, Mark
Delioukina, Maria
Kingsley, Edwin C.
Anh Tran
Ping, Jerry
Beaupre, Darrin M.
Neuenburg, Jutta K.
Ruan, Jia
BLOOD, 2016, 128 (22)
[43] ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL).
Oluwole, Olalekan O.
Bishop, Michael Russell
Gisselbrecht, Christian
Gordon, Leo I.
Kersten, Marie Jose
Maloney, David G.
Schmitz, Norbert
Barrigon, Maria Dolores Caballero
Kuruvilla, John
Song, Kevin W.
Jacobson, Caron A.
Nastoupil, Loretta J.
Riedell, Peter
Jiang, Yizhou
Rossi, John M.
Lee, Lillian
Cheng, Paul C.
Locke, Frederick Lundry
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[44] CPOP-R Versus CHOP-R As First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Phase 2, Randomized, Open-Label, Multicenter Study
Herbrecht, Raoul
MacDonald, David
Weissinger, Florian
Wilhelm, Martin
Holladay, Charles
Dang, Nam H.
Holman, Peter
Cernohous, Paul
Singer, Jack
van der Jagt, Richard H.
BLOOD, 2011, 118 (21) : 697 - 698
[45] A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)
Lee, Seung Tae
Pinto, Antonio
Yimer, Habte
Stevens, Don
Posluszny, Wanda Knopinska
Shum, Merrill Kingman
Manda, Sudhir
Leiba, Merav
Canales, Miguel
Kazmierczak, Maciej
Jurczak, Wojciech
Sureda, Anna
Ma, Xi Wen
Li, Kai
Ingalls, Kimberly
Arriola, Tara
Arazy, Melina
Shah, Jatin J.
Shacham, Sharon
Kauffman, Michael G.
Nowakowski, Grzegorz S.
BLOOD, 2021, 138
[46] Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL; OLYMPIA-5).
Vitolo, Umberto
Merli, Michele
Norasetthada, Lalita
Wassenaar, Timothy Robert
Martin, Eva Maria Donato
Bobillo, Sabela
Shen, Biyi
Flink, Dina M.
Zhu, Min
Chandrasekharan, Soujanya
Brouwer-Visser, Jurriaan
Chaudhry, Aafia
Mohamed, Hesham
Ambati, Srikanth R.
Cordoba, Raul
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[47] Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
Chen, Robert W.
Ansel, Stephen Maxted
Zinzani, Pier Luigi
Vacirca, Jeffrey L.
Lopez-Guillermo, Armando
Hutchings, Martin
Jurczak, Wojciech
Hess, Georg
Le Gouill, Steven
Offner, Fritz
Santoro, Armando
Salles, Gilles A.
Stypinski, Darla
Laird, Douglas
Pavlov, Dmitri
Andreola, Giovanna
Fly, Kolette D.
Woolfson, Adrian
Collins, Graham P.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[48] Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab (RW-CHOP) for Previously Untreated DLBCL: JCOG0601
Ohmachi, Ken
Kinoshita, Tomohiro
Tobinai, Kensei
Ogawa, Gakuto
Mizutani, Tomonori
Yamauchi, Nobuhiko
Fukuhara, Noriko
Uchida, Toshiki
Yamamoto, Kazuhito
Miyazaki, Kana
Tsukamoto, Norifumi
Iida, Shinsuke
Utsumi, Takahiko
Yoshida, Isao
Imaizumi, Yoshitaka
Tokunaga, Takashi
Yoshida, Shinichiro
Masaki, Yasufumi
Murayama, Tohru
Yakushijin, Yoshihiro
Suehiro, Youko
Nosaka, Kisato
Dobashi, Nobuaki
Kuroda, Junya
Takamatsu, Yasushi
Maruyama, Dai
Ando, Kiyoshi
Ishizawa, Kenichi
Ogura, Michinori
Yoshino, Tadashi
Hotta, Tomomitsu
Tsukasaki, Kunihiro
Nagai, Hirokazu
BLOOD, 2018, 132
[49] Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study
Herrera, Alex F.
Matasar, Matthew J.
Assouline, Sarit
Kamdar, Manali
Mehta, Amitkumar
Fleury, Isabelle
Kim, Won Seog
Kim, Tae Min
Bosch, Francesc
Radford, John A.
Bu, Lilian
Hong, Wan-Jen
Sehn, Laurie H.
BLOOD, 2016, 128 (22)
[50] B-MIND: MOR208 plus bendamustine (BEN) versus rituximab (RTX) plus BEN in patients with relapsed or refractory (R-R) diffuse large B-cell lymphoma (DLBCL): An open-label, randomized phase trial.
Nowakowski, Grzegorz S.
Belada, David
Molina, Lysianne
Kopeckova, Katerina
Laribi, Kamel
del Campo Garcia, Raquel
Coiffier, Bertrand
Jurczak, Wojciech
Rummel, Mathias J.
Hess, Georg
Rosenwald, Andreas
Winderlich, Mark
Korolkiewicz, Roman
Zinzani, Pier Luigi
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 →